Xenon Pharmaceuticals (XENE) Misses Q3 EPS by 25c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Xenon Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Corporate Update
November 10, 2015 4:30 PM ESTProgress Includes Initiation of XEN801 Phase 1 Clinical Trial and Achievement of Milestones in Genentech Nav1.7 Clinical Program and Pain Genetics Collaboration
Conference Call/Webcast Today at 5:00 p.m. Eastern Time
BURNABY, British Columbia, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the quarter ended September 30, 2015 and provided a corporate update.
Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, said, "We are pleased with our progress in the third quarter... More
